AMOEBA (EPA:AMEBA) - Amoeba publishes in Scientific Reports, a journal of the Nature Publishing group, the complete genomic analysis of the Willaertia magna C2c Maky amoeba.

Transparency directive : regulatory news

05/12/2019 18:00

PRESS RELEASE

AMOÉBA publishes in Scientific Reports, a journal of the Nature Publishing
group, the complete genomic analysis of the Willaertia magna C2c Maky amoeba.

Results that help to demonstrate the absence of pathogenicity of the amoeba

Lyon (France), December 05, 2019 - AMOÉBA (FR0011051598 - AMEBA), producer of
a biological biocide, capable of eliminating bacterial risk in water and human
wounds, and a biocontrol product for plant protection, still in the testing
phase, announces a major scientific publication. As the result of a
collaboration with the Institut Hospitalo-Universitaire de Méditerranée
Infection in Marseille, the article reports the complete sequencing and genome
analysis of the Willaertia magna C2c Maky amoeba. It is available at the
following address: www.nature.com/articles/s41598-019-54580-6

"Knowledge of non-pathogenic amoebas is limited, so sequencing the genome of
Willaertia magna C2c Maky is a major step forward in decoding its capabilities.
The study shows that this amoeba has a genome containing 36.5 million
nucleotide bases. It potentially codes for 18519 proteins, half of which could
be assigned to known functions. " explains Professor Bernard LA SCOLA of the
IHU de Méditerranée Infection.

This study is all the more essential as it strengthens the evidence of the
Willaertia magna C2c Maky amoeba safety. Indeed, 15 genes present in this
amoeba and showing similarity to virulence genes of the pathogenic amoeba
Naegleria fowleri have already been observed in the non-pathogenic amoeba
Naegleria gruberi, confirming that their presence is not a sign of
pathogenicity.

To consolidate this result, a cytotoxicity study on human endothelial cells was
performed. The results show that Willaertia magna C2c Maky has no effect on
these human cells while the pathogenic amoeba Balamuthia mandrillaris, used as
a control, has a toxic effect on them.

These results are in agreement with the absence of any case, human or animal,
of Willaertia magna C2c Maky infection and confirm the results of the toxicity
and pathogenicity studies conducted by Amoéba with this amoeba. Demonstrating
the absence of pathogenicity is a priority for the company, which goes well
beyond the regulatory studies required and carried out for the registration
dossiers of the biocidal active substance in Europe and the USA.

"We have extensively collaborated with renowned external laboratories without
ever publishing our results to date. Our scientific communication strategy is
now to illustrate our scientific expertise and that of our partners by
publishing all our research. This scientific article is, as such, the first in
a series of upcoming publications. "says Sandrine DEMANECHE, Scientific
Director of Amoéba.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba- biocide.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management
Technologies," Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors Relations
Grégory BOSSON
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

Medias relations
Constance LOZET
Agence Ekno
+33(0)7 78 41 19 70
constance.lozet@ekno.fr

Disclaimer

This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 25, 2019 under number D19-0383 (a copy of
which is available on www.amoeba-biocide.com). The forward-looking statements
contained in this press release are also subject to risks not yet known to
AMOEBA or not currently considered material by AMOEBA. The occurrence of all or
part of such risks could cause actual results, financial conditions,
performance or achievements of AMOEBA to be materially different from such
forward-looking statements.

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - Amoeba publishes in Scientific Reports, a journal of the Nature Publishing group, the complete genomic analysis of the Willaertia magna C2c Maky amoeba.

Transparency directive : regulatory news

AMOEBA's latest news

Other stories